IL155795A0 - Combination of drugs (e.g. chlorpromazine and pentamidine) for the treatment of neoplastic disorders - Google Patents

Combination of drugs (e.g. chlorpromazine and pentamidine) for the treatment of neoplastic disorders

Info

Publication number
IL155795A0
IL155795A0 IL15579501A IL15579501A IL155795A0 IL 155795 A0 IL155795 A0 IL 155795A0 IL 15579501 A IL15579501 A IL 15579501A IL 15579501 A IL15579501 A IL 15579501A IL 155795 A0 IL155795 A0 IL 155795A0
Authority
IL
Israel
Prior art keywords
pentamidine
chlorpromazine
drugs
treatment
combination
Prior art date
Application number
IL15579501A
Other languages
English (en)
Original Assignee
Combinatorix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorix Inc filed Critical Combinatorix Inc
Publication of IL155795A0 publication Critical patent/IL155795A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL15579501A 2000-11-06 2001-10-30 Combination of drugs (e.g. chlorpromazine and pentamidine) for the treatment of neoplastic disorders IL155795A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/706,929 US6569853B1 (en) 2000-11-06 2000-11-06 Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
PCT/US2001/047959 WO2002058684A2 (en) 2000-11-06 2001-10-30 Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders

Publications (1)

Publication Number Publication Date
IL155795A0 true IL155795A0 (en) 2003-12-23

Family

ID=24839666

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15579501A IL155795A0 (en) 2000-11-06 2001-10-30 Combination of drugs (e.g. chlorpromazine and pentamidine) for the treatment of neoplastic disorders

Country Status (29)

Country Link
US (4) US6569853B1 (xx)
EP (1) EP1339399B1 (xx)
JP (1) JP2004517915A (xx)
KR (1) KR100720205B1 (xx)
CN (1) CN1484525A (xx)
AR (1) AR035500A1 (xx)
AT (1) ATE318590T1 (xx)
AU (1) AU2002246636B8 (xx)
BG (1) BG107831A (xx)
BR (1) BR0115166A (xx)
CA (1) CA2436799C (xx)
CY (1) CY1105501T1 (xx)
DE (1) DE60117615T2 (xx)
DK (1) DK1339399T3 (xx)
EE (1) EE200300212A (xx)
ES (1) ES2258566T3 (xx)
HR (1) HRP20030460A2 (xx)
HU (1) HUP0400529A3 (xx)
IL (1) IL155795A0 (xx)
IS (1) IS2457B (xx)
MX (1) MXPA03003960A (xx)
NO (1) NO20032036L (xx)
NZ (1) NZ525773A (xx)
PL (1) PL362690A1 (xx)
PT (1) PT1339399E (xx)
RU (1) RU2286769C2 (xx)
SK (1) SK5452003A3 (xx)
TW (1) TWI259077B (xx)
WO (1) WO2002058684A2 (xx)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035935A2 (en) * 1999-11-16 2001-05-25 Oncozyme Pharma Inc. Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer
DE10015818A1 (de) * 2000-03-30 2001-10-18 Infineon Technologies Ag Biosensor und Verfahren zum Ermitteln makromolekularer Biopolymere mit einem Biosensor
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
WO2002057244A1 (en) * 2001-01-19 2002-07-25 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
WO2002069949A2 (en) * 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
AU2002312170B8 (en) * 2001-05-31 2008-07-31 The Cleveland Clinic Foundation PTPase inhibitors and method of using same
FR2825279B1 (fr) * 2001-06-01 2005-04-08 Molecular Engines Lab Medicament utile dans le traitement du cancer
WO2003070158A2 (en) * 2001-09-07 2003-08-28 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
US20040010045A1 (en) * 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
US20050215629A1 (en) * 2001-09-07 2005-09-29 Taolin Yi PTPase inhibitors and methods of using the same
AU2004201240B2 (en) * 2001-09-27 2008-08-07 Bar Ilan University Conjugated Psychotropic Drugs and Uses Thereof
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
AU2003241346A1 (en) * 2002-05-01 2003-11-17 The Cleveland Clinic Foundation Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
CA2492059A1 (en) * 2002-07-11 2004-01-22 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
EP1606759B1 (en) * 2003-03-26 2010-05-05 Synergy Biosystems Ltd. Methods to identify biologically active agents and synergistic combinations
EP2377528B1 (en) * 2003-06-12 2014-02-19 The Board of Regents of the University of Colorado Fatty acid metabolism inhibitors for use in the treatment of cancer
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
WO2005020913A2 (en) * 2003-08-25 2005-03-10 Combinatorx, Incorporated Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
RU2006112834A (ru) * 2003-09-18 2007-10-27 Комбинаторкс, Инкорпорейтед (Us) Сочетание лекарственных средств для лечения новообразований
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
TW200526777A (en) * 2003-11-12 2005-08-16 Combinatorx Inc Combinations for the treatment of proliferative diseases
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US8623864B2 (en) 2003-11-13 2014-01-07 Noa Sic Aps Thioridazine and derivatives thereof for reversing anti-microbial drug-resistance
WO2005070126A2 (en) 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
SI2574341T1 (sl) 2004-03-29 2017-08-31 University Of South Florida Učinkovito zdravljenje tumorjev in raka s triciribin fosfatom
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
EA016803B1 (ru) 2004-04-30 2012-07-30 Бкг Фарма Апс Лечение инфекционных заболеваний
WO2005117847A2 (en) * 2004-06-02 2005-12-15 Combinatorx, Incorporated Methods and compounds for the treatment of neoplasms
US20080269259A1 (en) * 2005-01-19 2008-10-30 The Trustees Of The University Of Pennsylvania Regulation of Autophagy and Cell Survival
TW200719903A (en) * 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
JP2008539238A (ja) * 2005-04-28 2008-11-13 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド 治療用二機能性化合物
US8329753B2 (en) * 2005-05-02 2012-12-11 The Regents Of The University Of Colorado Combination of compounds, or a bifunctional compound, that provides fatty acid metabolism and glycolysis inhibition
WO2006117220A2 (en) 2005-05-04 2006-11-09 Medigene Ag Method of administering a cationic liposomal preparation comprising paclitaxel
DE102005024017A1 (de) * 2005-05-25 2006-11-30 Merck Patent Gmbh Chinazolinone
WO2006131923A2 (en) * 2005-06-07 2006-12-14 Ramot At Tel Aviv University Ltd. Novel salts of conjugated psychotropic drugs and processes of preparing same
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
TW200803835A (en) * 2006-01-11 2008-01-16 Cleveland Clinic Foundation Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
EP3056196A1 (en) 2006-03-22 2016-08-17 SynCore Biotechnology CO., LTD Treatment of triple receptor negative breast cancer
WO2007149381A2 (en) * 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Compositions comprising a ptp-ase inhibitor and use thereof in treating cancer
US20080226596A1 (en) * 2006-06-19 2008-09-18 Taolin Yi Therapeutic compositions and methods useful in treating hepatitis
EP2051735B1 (en) * 2006-07-17 2012-08-29 Ramot, at Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use treating pain and other cns disorders
WO2008080398A1 (en) 2007-01-05 2008-07-10 Bkg Pharma Aps Anti - infective agents such as phenothiazine and thioxanthene derivates to treat infectious diseases
CA2674877C (en) * 2007-01-09 2016-03-15 Fovea Pharmaceuticals Apparatus for intra-ocular injection
DE102007013854A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Tetrahydrochinoline
DE102007013856A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydropyrrolochinoline
DE102007013855A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydrochinoline
CA2687715A1 (en) * 2007-05-09 2008-11-20 Traffick Therapeutics Inc. Screening assay to identify correctors of protein trafficking defects
CN101138558B (zh) * 2007-09-13 2010-08-25 汕头大学医学院 喷他脒及死亡结构域受体配体联合应用
ATE534389T1 (de) * 2007-10-05 2011-12-15 Univ Mons Hainaut Bisbenzimidazole und mittel gegen malaria
US8207369B2 (en) * 2008-02-11 2012-06-26 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
EP2318008A1 (en) * 2008-07-18 2011-05-11 Immune Control, Inc. Binding and inhibiting 5-ht4 receptor
US8993625B2 (en) * 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
JP2012525371A (ja) * 2009-05-01 2012-10-22 オンコザイム・ファーマ・インコーポレイテッド 癌を治療するためのペンタミジンの組み合わせ
CN102439453A (zh) 2009-05-20 2012-05-02 日内瓦大学 癌症起始细胞的线粒体活性抑制剂及其用途
WO2011035225A1 (en) * 2009-09-21 2011-03-24 President And Fellows Of Harvard College Synergistic combination therapy
BR112012013639A2 (pt) * 2009-12-09 2017-04-04 Bar-Ilan Univ "métodos pára melhorar funções congnitivas"
WO2011133966A2 (en) * 2010-04-23 2011-10-27 University Of Florida Research Foundation,Inc. Method and compositions for treating ace2-related disorders
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
RS55557B1 (sr) * 2011-07-25 2017-05-31 Dritte Patentportfolio Beteili Amidoksimski estri karboksilnih kiselina pentamidina kao prolekovi i njihova primena kao lekova
JP6069321B2 (ja) * 2011-08-02 2017-02-01 ヘルムホルツ ツェントラム ミュンヘン ドイチェス フォーシュングスツェントラム フュール ゲズントハイト ウント ウンヴェルト ゲーエムベーハーＨｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ Ｍｕｅｎｃｈｅｎ Ｄｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ Ｕｎｄ Ｕｍｗｅｌｔ Ｇｍｂｈ フェノチアジン誘導体によるｍａｌｔ１プロテアーゼの選択的阻害
WO2014086478A1 (en) * 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
US9375411B2 (en) * 2012-12-21 2016-06-28 Verlyx Pharma Inc. Uses and methods for the treatment of liver diseases or conditions
RU2530651C1 (ru) * 2013-11-06 2014-10-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, обладающее противовоспалительным и антифибротическим действием в легочной ткани при цитостатическом воздействии
KR101538264B1 (ko) * 2014-01-24 2015-07-20 계명대학교 산학협력단 티오리다진과 트레일을 유효성분으로 함유하는 암 예방 또는 치료용 약학조성물
CN105125571B (zh) * 2015-07-17 2018-11-06 四川大学 Prmt1抑制剂在制备治疗可卡因成瘾的药物中的用途
WO2020082037A1 (en) * 2018-10-19 2020-04-23 Auransa Inc. Methods for treating a subtype of small cell lung cancer
CN109793727A (zh) * 2019-03-13 2019-05-24 湖北科技学院 一种有效抗恶性肿瘤的药物组合物及其应用
KR102562739B1 (ko) * 2020-09-11 2023-08-03 연세대학교 산학협력단 암의 기원 세포의 사멸용 약학적 조성물
KR102315103B1 (ko) * 2021-01-21 2021-10-20 주식회사 뉴캔서큐어바이오 티오리다진 및 퍼헥실린을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2645640A (en) 1953-07-14 Phenthiazine derivatives
GB1288376A (xx) 1968-10-29 1972-09-06
DE3827974A1 (de) 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US5104858A (en) 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
CH681780A5 (en) * 1991-02-25 1993-05-28 Patrinove Anticancer compsns. - consists of a cytotoxic agent with a agent to prevent multi:drug resistance, e.g. in liposome(s)
US5428051A (en) 1992-10-13 1995-06-27 University Of North Carolina Methods of combating pneumocystis carinii pneumonia and compounds useful therefor
US5443962A (en) 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
US5602172A (en) 1994-05-06 1997-02-11 The University Of North Carolina At Chapel Hill Methods of inhibiting Pneumocystis carinii pneumonia, Giardia lamblia, and Cryptosporidium and compounds useful therefor
US5521189A (en) 1994-05-06 1996-05-28 The University Of Nc At Ch Methods of treating pneumocystis carinii pneumonia
US5770585A (en) 1995-05-08 1998-06-23 Kaufman; Robert J. Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal
US5643935A (en) 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
US5723495A (en) 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
AU3511197A (en) 1996-07-03 1998-01-21 Prm Pharmaceuticals, Inc. Berberine alkaloids as a treatment for chronic, protozoally-induced diarrhea
US6008247A (en) 1998-02-27 1999-12-28 The University Of North Carolina At Chapel Hill 2,4-bis[(4-amidino)phenyl]furans as anti-Pneumocystis carinii agents
JP2004500308A (ja) 1998-03-12 2004-01-08 ノボ　ノルディスク　アクティーゼルスカブ プロテインチロシンホスアターゼのモジュレーター
DE69907476T2 (de) 1998-08-20 2004-04-15 The University Of North Carolina At Chapel Hill Office Of Technology Development Dibenzothiophene derivate und ihre verwendung
ES2275362T3 (es) 1998-09-17 2007-06-01 The University Of North Carolina At Chapel Hill Actividad antifungica de moleculas dicationicas.
JP3679943B2 (ja) * 1999-03-02 2005-08-03 大日本印刷株式会社 パターン形成体の製造方法
WO2001035935A2 (en) 1999-11-16 2001-05-25 Oncozyme Pharma Inc. Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer
US6777433B2 (en) 1999-12-22 2004-08-17 Merck Frosst Canada & Co. Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
US6911468B2 (en) 2000-05-22 2005-06-28 Takeda Chemical Industries, Ltd. Tyrosine phosphatase inhibitors
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6642221B1 (en) 2000-11-15 2003-11-04 Parker Hughes Institute Vanadium compounds as anti-proliferative agents
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20030161893A1 (en) 2001-09-07 2003-08-28 Taolin Yi PTPase inhibitors and methods of using the same
CA2492059A1 (en) 2002-07-11 2004-01-22 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
US20050054708A1 (en) 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
WO2005020913A2 (en) 2003-08-25 2005-03-10 Combinatorx, Incorporated Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
RU2006112834A (ru) 2003-09-18 2007-10-27 Комбинаторкс, Инкорпорейтед (Us) Сочетание лекарственных средств для лечения новообразований
US20050100508A1 (en) 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US20050158320A1 (en) 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases

Also Published As

Publication number Publication date
WO2002058684A2 (en) 2002-08-01
AR035500A1 (es) 2004-06-02
IS6806A (is) 2003-05-05
US20070099906A1 (en) 2007-05-03
HUP0400529A2 (hu) 2004-06-28
NO20032036D0 (no) 2003-05-06
EP1339399A2 (en) 2003-09-03
CA2436799C (en) 2007-12-18
BR0115166A (pt) 2003-12-30
US20030166642A1 (en) 2003-09-04
MXPA03003960A (es) 2004-09-10
AU2002246636B2 (en) 2005-12-01
PT1339399E (pt) 2006-07-31
EP1339399B1 (en) 2006-03-01
ATE318590T1 (de) 2006-03-15
HRP20030460A2 (en) 2005-04-30
CN1484525A (zh) 2004-03-24
SK5452003A3 (en) 2004-07-07
EE200300212A (et) 2003-08-15
AU2002246636B8 (en) 2006-01-19
DE60117615T2 (de) 2006-11-09
IS2457B (is) 2008-11-15
BG107831A (bg) 2004-02-27
US20050192274A1 (en) 2005-09-01
KR20030048460A (ko) 2003-06-19
WO2002058684A3 (en) 2003-04-17
JP2004517915A (ja) 2004-06-17
NO20032036L (no) 2003-07-04
ES2258566T3 (es) 2006-09-01
RU2286769C2 (ru) 2006-11-10
US6569853B1 (en) 2003-05-27
US7148216B2 (en) 2006-12-12
CA2436799A1 (en) 2002-08-01
PL362690A1 (en) 2004-11-02
DE60117615D1 (de) 2006-04-27
HUP0400529A3 (en) 2006-02-28
TWI259077B (en) 2006-08-01
NZ525773A (en) 2005-04-29
CY1105501T1 (el) 2010-04-28
KR100720205B1 (ko) 2007-05-21
DK1339399T3 (da) 2006-06-19
US6846816B2 (en) 2005-01-25

Similar Documents

Publication Publication Date Title
IL155795A0 (en) Combination of drugs (e.g. chlorpromazine and pentamidine) for the treatment of neoplastic disorders
EP1363625A4 (en) COMBINATIONS OF DRUGS (eg, BENZIMIDAZOLE AND PENTAMIDINE) IN THE TREATMENT OF NEOPLASTIC DISORDERS
ZA200300434B (en) Medicinal herbal compounds for the prevention and treatment of diabetes.
IL196301A0 (en) Medicament for the treatment of hapatitis c
HUP0103856A2 (hu) Gyógyszerkészítmény akut rendellenességek kezelésére
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
ZA200202542B (en) Treating sleep disorders using desloratadine.
HK1020261A1 (en) Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumours, tumour-related disorders and cachexia
HK1051690A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain.
ZA200107689B (en) 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.
AU2001268710A1 (en) Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
HK1041827A1 (en) Compounds for the treatment of estrogen-defendent illnesses and methods for making and using the dame.
DK1041985T3 (da) Kombination af benzocycloheptapyridinforbindelser og antineoplastiske lægemidler til behandling af profilerative sygdomme
IL150289A0 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
ZA200205098B (en) Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.
HUP0401913A3 (en) Medicine for preventing and treating bromhidrosis
GB0128674D0 (en) Treatment of sleep disorders and the like
ZA200007111B (en) Methods and devices for providing prolonged drug therapy.
MXPA03003032A (es) Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.
PL347976A1 (en) Isonipecotamides for the treatment of integrin−mediated disorders
MXPA03001472A (es) Compuestos para el tratamiento de trastornos adictivos.
AU6274101A (en) Medicines for the prevention and treatment of neurodegenerative diseases